
ABSTRACT Introduction Wearable cardioverter defibrillators (WCDs) protect patients at elevated risk of sudden cardiac death (SCD) but are effective only when worn. The ASSURE WCD was designed to address historical limitations related to false alarms and patient adherence. The objective of this post‐approval study was to assess safety and effectiveness in a large, real‐world cohort. Methods The study population was comprised of patients meeting WCD indications who were fitted with the ASSURE WCD. The primary effectiveness endpoint was overall shock conversion success for ventricular tachycardia (VT) or ventricular fibrillation (VF) (performance goal ≥ 89%), and the primary safety endpoint was the incidence of inappropriate shocks (performance goal ≤ 0.0075 per patient‐month). Results Among 21 612 patients (mean age 64.0 years, 33.9% female), median daily use was 23.1 h/day (IQR 16.1–23.9) over 54 days (IQR 20–97). WCD indications included cardiomyopathy (63.8%), post‐myocardial infarction (19.3%), sustained VT/VF (11.9%) and ICD explant/other (5.0%). Both primary effectiveness and safety endpoints were met. All 303 VT/VF shock events in 261 patients (1.2%) were successfully converted, yielding an overall shock conversion success of 100% (95% CI: 98.8%–100%), with first‐shock success of 97.0% (95% CI: 94.4%–98.5%). The incidence rate of inappropriate shocks was 0.0065 per patient‐month (95% CI: 0.0057–0.0073). False‐positive alarms occurred in 6.0% of patients. The 90‐day Kaplan–Meier estimated risk of VT/VF was 3.4%, varying by WCD indication ( p < 0.001) but not by left ventricular ejection fraction ( p = 0.16). Conclusion In routine practice, the ASSURE WCD effectively terminated VT/VF with low false alarm and inappropriate shock rates and high patient adherence. Most VT/VF events occurred early during WCD wear. Collectively, these findings provide important contemporary evidence to inform the selection of patients who may benefit from WCD therapy during periods of elevated arrhythmic risk. Trial Registration NCT05135403.
ABSTRACT Background Atrial fibrillation (AF) increases ischemic stroke risk nearly fivefold. Although the CHA 2 DS 2 ‐VA score is widely used for risk stratification, its predictive performance is limited, particularly in intermediate‐risk patients. Left atrial (LA) enlargement, a marker of structural remodeling, may improve risk prediction. Aims To evaluate whether adding LA diameter to CHA 2 DS 2 ‐VA (creating CHA 2 DS 2 ‐VALa) enhances ischemic stroke prediction in AF patients. We additionally derived a multivariable β‐weighted model and benchmarked its performance against CHA 2 DS 2 ‐VA (and the simplified +1 LA rule). Methods This retrospective study included 1648 AF patients. LA diameter was measured by standardized echocardiography. A ROC‐derived cut‐off (> 4.7 cm) defined enlargement. Patients were followed for a mean of 4.18 ± 0.35 years. Imaging‐confirmed ischemic stroke events were identified through institutional hospital records and the electronic health registry, and were validated using hospitalization documentation, neurology consultation notes, discharge summaries, and available brain CT/MRI findings. Predictors were assessed using multivariable logistic regression, and Kaplan–Meier/log‐rank analyses compared CHA 2 DS 2 ‐VALa versus CHA 2 DS 2 ‐VA. Results Imaging‐confirmed ischemic stroke events occurred more frequently in patients with LA > 4.7 cm (25 [3.8%] vs. 21 [2.1%], p < 0.001). Elevated CRP, NT‐proBNP, diabetes, hypertension, CAD, and heart failure were also associated with stroke. LA > 4.7 cm independently predicted events (OR 1.97, 95% CI 1.36–2.86, p < 0.001). ROC analysis showed strong discrimination for LA diameter (AUC 0.872; sensitivity 82%, specificity 85%). Kaplan–Meier analysis demonstrated superior prediction with CHA 2 DS 2 ‐VALa compared to CHA 2 DS 2 ‐VA (log‐rank p < 0.001). Conclusion The CHA 2 DS 2 ‐VALa score significantly improves stroke risk stratification in AF by integrating LA diameter into conventional scoring. As echocardiographic measurement is widely available and reproducible, this modification offers a simple, pragmatic approach to refine residual stroke‐risk stratification and support closer evaluation and follow‐up in anticoagulated AF patients. Prospective validation in diverse populations is warranted.
ABSTRACT Introduction Left atrial low‐voltage zones (LVZs) are associated with atrial fibrosis and arrhythmia recurrence after atrial fibrillation (AF) ablation and are thought to underlie many recurrences despite durable pulmonary vein isolation. However, noninvasive markers of the arrhythmogenic atrial substrate remain poorly characterized. We sought to investigate the association between computed tomography (CT)–derived left atrial intramyocardial fat (inFAT) and electroanatomically defined LVZs. Methods and Results In this single‐center retrospective study, 145 consecutive patients undergoing first‐time radiofrequency AF ablation underwent preprocedural dual‐source CT and high‐density left atrial voltage mapping in sinus rhythm. LVZs were defined as contiguous regions with bipolar voltage < 0.5 mV. ADAS 3D post‐processing was used to quantify total inFAT, dense inFAT, and fat–myocardial admixture. LVZs were identified in 51 patients (35.2%). Compared with patients without LVZs, those with LVZs had a higher prevalence of persistent AF (58.8% vs. 17.0%; p < 0.001) and a greater left atrial volume index (LAVi) (74.41 [64.87–99.50] vs. 62.99 [52.78–74.73] mL/m 2 ; p < 0.001). Patients with LVZs also demonstrated larger volumes of total inFAT, dense inFAT, and fat–myocardial admixture, accompanied by lower radiodensity values of total and dense inFAT. In multivariable logistic regression analysis, persistent AF (adjusted odds ratio [OR]: 5.389; 95% confidence interval [CI]: 2.162–13.433; p < 0.001) and dense inFAT volume (adjusted OR: 3.439; 95% CI: 1.107–10.677; p = 0.033) remained independently associated with the presence of LVZs, whereas LAVi did not. Among the CT‐derived fat metrics, only dense inFAT retained an independent association with LVZs after adjustment for clinical covariates. Conclusion CT‐derived dense inFAT was independently associated with left atrial LVZs and may represent a novel noninvasive marker of the arrhythmogenic atrial substrate in AF. Prospective studies are warranted to determine its role in substrate‐guided ablation strategies and risk stratification.
ABSTRACT Background The health of pilots is essential for aviation safety and the well‐being of passengers. Cardiovascular disease poses the greatest medical threat to flight safety and is the leading cause of lost certification for pilots. Methods Public notification of a recent Federal Aviation Administration (FAA) decision granting licensure to pilots with cardiovascular disease and implanted defibrillators is notable. Results A Delta Airlines first officer received a Class A pilot license despite experiencing a full cardiac arrest (with ventricular fibrillation) in the cockpit 6 h into a transatlantic flight at 40 000 feet, resulting in incapacitation and requiring (successful) cardiopulmonary resuscitation by the captain with an on‐board emergency automatic external defibrillator. The pilot soon thereafter received an implantable cardioverter‐defibrillator for secondary prevention of sudden death. Electrophysiologic study demonstrated active LV arrhythmogenic foci leading to attempted myocardial ablation. After extensive litigation, the pilot was ultimately issued an unrestricted special issuance medical certificate, the first such FAA decision for a civilian pilot with an active implanted defibrillator and representing a major reversal of long‐standing aeromedical policy and standards. Conclusions This novel liberalized practice of the FAA and NTSB as regulatory agencies, certifying at‐risk pilots with active defibrillators that could deliver powerful appropriate therapy or inappropriate shocks in the cockpit, raises legitimate concerns regarding the impact of such decisions on aviation safety and the confidence of the flying public.